Search Results

Calaspargase pegol-mknl

Calaspargase pegol-mknl is FDA approved as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years. 

 

Deciphering the interplay between apoptotic and signaling pathways to target T-lineage acute lymphoblastic leukemia

T-ALL is an aggressive leukemia with limited treatment options. T-ALL cells resist to dying by suppressing their suicide pathways. BH3 mimetics reactivate the suicide mechanisms to induce cell death. We showed that these drugs are effective in T-ALL, but acquired resistance is due to the activation of growth-promoting signaling pathways. The proposed experiments will decipher the relationship between growth and death pathways, identifying unique combination therapies to improve disease outcomes.

Improving CAR T-cell Therapy Efficacy in Acute Lymphoblastic Leukemia by Optimizing Design and Placement

Pediatric acute lymphoblastic leukemia (ALL) that is resistant to standard therapy is a challenge that has been partially overcome by T-cell therapy, yet relapse still occurs in up to 50%. We are conducting two clinical trials that test a next-generation T-cell therapy and the first incorporation of T-cell therapy into initial therapy. These trials will inform future development and the optimal place for this therapy with the goal of improving cure rates for children with very high risk ALL.

Paying Tribute to a Legacy: Executive Challenge Winners Recognized

This year’s Light The Night Executive Challenge ended with a bittersweet roundup of results. The winner, Stacey Weathers, former long-time executive director of The Leukemia & Lymphoma Society’s (LLS) New Jersey chapter, was tragically killed this past October when a tree fell on her car during a storm. Even though she isn’t here to celebrate with her LLS colleagues and family, her worthy achievement will be recognized as her legacy lives on.  

A Powerful Force

How Celebrating My 18th Birthday in the Hospital Changed My Perspective

Marlee’s story of courage, inspiration and giving back.

 

My name is Marlee Pincus and I have cancer. I never in a million years thought I would say those words. Growing up, I never had any medical issues nor a significant family history of cancer. In high school I loved to run, advocate for human rights, and learn Spanish. However, my greatest focus was always on my academics. I graduated Salutatorian of my class and was eager to begin my freshman year at Cornell University. 

Where Blood Cancer Meets Nature: Why This Scholarship Recipient Is Saving the Earth

When we think about the future, a lot can feel uncertain—especially as a teenager or young adult (AYA) with blood cancer.  

We get it.  

Nelarabine

Nelarabine is FDA approved to treat people who have relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma following treatment with at least two chemotherapy regimens.

Pentostatin

Pentostatin is FDA approved as a single-agent treatment for both untreated and alfa-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia (abnormally low white blood count), thrombocytopenia (reduced platelet count), or disease-related symptoms.

Asparaginase

Asparaginase is FDA approved in combination with chemotherapy to treat people who have acute lymphoblastic leukemia.

Quizartinib

Quizartinib is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. 

When The Time Comes: Katie & Phil’s Story

A Special Surprise for Pediatric Cancer Patient Counting Down the Days until Treatment Ends

"A Style for Every Smile” Campaign is Brightening the Faces of Pediatric Cancer Patients like 4-Year-Old Sasha Nationwide

At the tender age of four, Sasha has endured more than most of us will in a lifetime. In October 2017, at just two years old, she was diagnosed with acute lymphoblastic leukemia, a diagnosis no parent wants to hear.

"It sounds so stereotypical, but I just didn't believe it. I was completely in denial,” says Sasha’s mom, Randi.

Leukemia Patient’s Legacy Helps Drive Innovative Cancer Clinical Trial

UCLA Health Joins The Leukemia & Lymphoma Society’s Innovative Clinical Trial

Burlington Stores Raises More Than $37M For The Leukemia & Lymphoma Society

FDA Approval: LLS Applauds New Advance for Acute Lymphoblastic Leukemia

The Leukemia & Lymphoma Society Kicks Off Light The Night Fall Campaign

LLS National Research Registry Progress Report - Chronic Lymphocytic Leukemia

Targeting non-genetic mechanisms of therapeutic resistance in Acute Myeloid Leukaemia

Drug resistance in AML can develop via a non-genetic process which remains poorly understood. Using our novel cellular barcoding technology that can trace the growth of thousands of cancer cells, our research will identify genes that are switched on or off in AML cells that lead to drug resistance and relapse. This work will reveal the factors underpinning non-genetic drug resistance that may be targeted with new drugs to prevent relapse and ultimately improve quality of life and survival.

PhRMA Recognized as 2013 "Titan of Business & Philanthropy" At the Annual Leukemia Ball

Rgenta Therapeutics Joins The Leukemia & Lymphoma Society Therapy Acceleration Program

FDA Approves First Targeted Treatment for Newly Diagnosed Leukemia Subtype

Functionalizing novel PHIP variants in ancestry specific Acute Myeloid Leukemia

AML risk stratification established by previous studies do not reflect survival outcomes observed in Black patients. Exome sequencing of 100 Black AML patients revealed the novel variants previously not affiliated with AML, including PHIP. Using multiomic patient sample captures and GEMMs, we will functionalize variants in PHIP and assess if they drive leukemogenesis and/or therapy resistance. The overall goal of this work is to implement inclusive genetic assessment tools for AML diagnosis.